| Bioactivity | AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells[1]. | ||||||||||||
| Name | AGPS-IN-1 | ||||||||||||
| CAS | 2316782-88-2 | ||||||||||||
| Formula | C18H17F2N3O2 | ||||||||||||
| Molar Mass | 345.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Stazi G, et al. Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells. Eur J Med Chem. 2019 Feb 1;163:722-735. |
AGPS-IN-1
CAS: 2316782-88-2 F: C18H17F2N3O2 W: 345.34
AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.